Inhibitors of IL-1, such as anakinra (IL-1 receptor antagonist, IL-1ra) and canakinumab (a monoclonal antibody against IL-1β), are used to treat conditions like rheumatoid arthritis and certain autoinflammatory syndromes (Gaggiano et al., 2021; Sanz-Cabanillas et al., 2023). Here, IL1B is linked to rheumatoid arthritis.